Alteogen Signs $365 Million Licensing Deal for Subcutaneous Drug Delivery Platform ALT-B4
Biotechnology firm Alteogen has signed an exclusive technology-transfer agreement worth up to $365 million (approximately 521.
Search results for "pharmaceutical sales"
Licensing Windfalls and Exports Split Performance Among Korea’s Top Drugmakers in Q2
South Korea’s five major legacy pharmaceutical companies largely extended their revenue growth in the second quarter, but their bottom lines diverged...
Yuhan Ramps Up OTC Magnesium Push with Dual-Campaign for Liquid and High-Dose 'MagV'
If your lower eyelid twitches or you experience sudden leg cramps, it is common to assume a magnesium deficiency is to...
Daewoong Pharmaceutical’s Nabota Enters Kuwait, Expanding Middle East Footprint to Seven Countries
Daewoong Pharmaceutical’s botulinum toxin product Nabota has entered Kuwait, expanding its Middle East footprint to...
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway
"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Ilyang Pharmaceutical Commits 17.6 Billion Won to China Comeback with Flagship Wonbi-D
Ilyang Pharmaceutical is mounting a fresh push into the Chinese market, reviving a business operation that had been...
Korea’s Healthcare Paradox: Near-Bottom Physician Ranks Meet Top-Tier Life Expectancy
Hospital waiting rooms across South Korea are perpetually packed, where a 30-minute wait remains a routine part of any...
31 Bottles Per Person: Kwangdong Corn Silk Tea Marks 20th Anniversary With 1.6 Billion Bottles Sold
For South Koreans looking for a refreshing, caffeine-free beverage, it is a staple that almost everyone has tried at...
AI Cancer Gene Analysis and 810 Billion-Won Tech Export Lead South Korea's Top 30 Health Care R&D Achievements
The Ministry of Health and Welfare and the Korea Health Industry Development Institute announced on the 8th that they...
Daewoong Pharmaceutical Secures 145.2 Billion Won MENA Export Deal for Diabetes Drug Enblo
Daewoong Pharmaceutical’s proprietary type 2 diabetes treatment, Enblo (active ingredient: enavogliflozin), is set to...